Literature DB >> 17460452

Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.

Tehmina Z Ali1, Jonathan I Epstein.   

Abstract

We studied 29 cases of basal cell carcinoma of the prostate including what others call adenoid cystic carcinoma of the prostate. Patients' age ranged from 42 to 89 (mean 69) years. The most common methods of diagnosis was transurethral resection (TURP) (n=29) and needle biopsy (n=9). In 28/29 cases, slides were reviewed and 24 (86%) cases showed more than 1 pattern: adenoid cysticlike (AC-P) pattern and small solid nests with peripheral palisading were the most predominant patterns, each seen in 18 cases (64%). Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis. Fourteen cases of small nests and tubules were centrally lined by eosinophilic cells. Desmoplasia was noted in 20 (71%) cases. Infiltration around benign glands was seen in 10 (36%) cases, with predominantly small nests and AC-P. Invasion of thick muscle bundles of the bladder neck was seen in 10 of 21 TURP cases. Perineural invasion was noted in 3 cases with AC-P and 1 case of small basaloid nests. Perineural and vascular invasion was seen in 2 basal cell carcinomas with large basaloid nests. Mitoses ranged from 0 to 60/10 hpf (mean=4). bcl2 was diffusely positive in 22/24 (92%) cases. Ki67 ranged from 2% to 80% (mean=23%). Ki67 > or =20% was seen in 13 (56.5%) cases, including all patterns except small solid nests. Basal cell markers (HMWCK, p63) either: (1) highlighted multiple layers of cells in 15/25 (60%) cases with sparing of the inner most luminal layer; (2) labeled just the outermost layers in 6/25 (24%) cases; or (3) reacted with only a few scattered cells in 4/25 (16%) cases (3 with large solid nests with central necrosis, 1 with tubules and cords). Seven patients had RP with: 5/7 showing extraprostatic extension with 1/5 also showing seminal vesicle involvement and 2/5 also with a positive margin; 1/7 having organ confined disease; and 1/7 showing no residual disease. An additional 11 cases showed extraprostatic extension on TURP with bladder neck invasion (n=10) or periprostatic adipose tissue invasion (n=1). Of 29 (65.5%) cases, 19 had follow-up > 1 year with a mean of 4.3 years (1 to 19 y). Of 19 (77%) cases, 14 had no evidence of disease after 1 to 19 (mean 5.8) years. Of 19 patients, 4 locally recurred with 2 after TURP, 1 after enucleation, and 1 after RP. Metastases developed in 4/29 patients: 1 in lung, 1 in lung and liver, 1 in lung, bone and liver, 1 in penile urethra. Basal cell carcinomas are rare tumors with a broad morphologic spectrum. These tumors predominantly show an indolent course with local infiltrative behavior. A small subset behaves aggressively with local recurrences and distant metastases. The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460452     DOI: 10.1097/01.pas.0000213395.42075.86

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

Review 1.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.

Authors:  Nahyun Choi; Boyu Zhang; Li Zhang; Michael Ittmann; Li Xin
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

3.  PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells.

Authors:  Seong M Kim; Tricia T Nguyen; Archna Ravi; Peter Kubiniok; Brendan T Finicle; Vaishali Jayashankar; Leonel Malacrida; Jue Hou; Jane Robertson; Dong Gao; Jonathan Chernoff; Michelle A Digman; Eric O Potma; Bruce J Tromberg; Pierre Thibault; Aimee L Edinger
Journal:  Cancer Discov       Date:  2018-03-23       Impact factor: 39.397

4.  Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinoma.

Authors:  Kazumasa Komura; Teruo Inamoto; Motomu Tsuji; Naokazu Ibuki; Kohei Koyama; Takanobu Ubai; Haruhito Azuma; Yoji Katsuoka
Journal:  Int J Clin Oncol       Date:  2010-04-27       Impact factor: 3.402

Review 5.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

Review 6.  The many ways to make a luminal cell and a prostate cancer cell.

Authors:  Douglas W Strand; Andrew S Goldstein
Journal:  Endocr Relat Cancer       Date:  2015-08-25       Impact factor: 5.678

7.  Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.

Authors:  Houjian Cai; Sanaz Memarzadeh; Tanya Stoyanova; Zanna Beharry; Andrew S Kraft; Owen N Witte
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

8.  A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate.

Authors:  Lin He; Christopher Metter; Vitaly Margulis; Payal Kapur
Journal:  Case Rep Pathol       Date:  2021-05-04

Review 9.  Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature.

Authors:  Kun Chang; Bo Dai; YunYi Kong; YuanYuan Qu; JianNong Wu; DingWei Ye; XuDong Yao; ShiLin Zhang; HaiLiang Zhang; Yao Zhu; WeiQiang Yao
Journal:  World J Surg Oncol       Date:  2013-08-13       Impact factor: 2.754

10.  Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: How can we detect prior to benign prostatic hyperplasia surgery?

Authors:  Eiichiro Ohara; Hiroshi Aoki; Yosuke Arakawa; Atsushi Kato; Rie Shibuya; Shigeto Ishidoya
Journal:  IJU Case Rep       Date:  2021-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.